Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Protagonist Therapeutics Inc (PTGX): RA Capital Management Acquires 6.8% Stake

Page 1 of 7

Peter Kolchinsky‘s RA Capital Management reported via a recent 13G filing with the SEC that it has taken a new position in a company that has recently gone public, Protagonist Therapeutics Inc (NASDAQ:PTGX). The new stake consists of 1.11 million common shares, which amass 6.8% of the company’s outstanding stock.

Protagonist Therapeutics Inc (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company that is working on discovering and manufacturing peptide-based new chemical entities for treatment of unresolved medical conditions. Recently, the company gained SBIR Funding for the development of Injectable Hepcidin Mimetics for the treatment of iron overload disorders. Since the company started trading on August 12, its stock has lost 8.46%.

Peter Kolchinsky

RA Capital is the second fund in our database to have revealed taking a large stake in the newly-public company; Phill Gross and Robert Atchinson’s Adage Capital Management reported owning 1.58 million shares of the company last week, with the position representing 9.69% of Protagonist Therapeutics Inc (NASDAQ:PTGX)’s stock.

Follow Protagonist Therapeutics Inc
Trade (PTGX) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 1,109,229 0 1,109,229 1,109,229 6.8%
Peter Kolchinsky 0 1,109,229 0 1,109,229 1,109,229 6.8%
RA Capital Healthcare Fund 0 909,203 0 909,203 909,203 5.6%

Peter Kolchinsky
Peter Kolchinsky
RA Capital Management

Page 1 of 7 – SEC Filing

Washington, D.C. 20549


Under the Securities Exchange Act of

(Amendment No. __)*

Protagonist Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per

(Title of Class of Securities)


(CUSIP Number)

August 16, 2016

(Date of Event Which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Page 1 of 7

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!